(lp0
S'Trovagene and Nerviano Announce License Agreement for therapeutic candidate ... PR Newswire  - Mar 15, 2017 SAN DIEGO and NERVIANO, Italy, March 15, 2017 /PRNewswire/ -- Trovagene, Inc. , a precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.Trovagene nabs rights to leukemia candidate from Nerviano Medical - Seeking AlphaWhy TrovaGene Inc  Reported Restructuring Plan? - StockNewsUnion'
p1
aS'Earnings Reaction History: TrovaGene, Inc., 75.0% Follow-Through Indicator, 7 ... Nasdaq - Mar 15, 2017 TrovaGene, Inc.  is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement.'
p2
aS'Trovagene Announces Broadening Network of Commercial Distributors PR Newswire  - Jan 12, 2017 SAN DIEGO, Jan. 12, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  technologies, today announced that it has signed agreements with seven strategic partners across Europe and the Middle East for&nbsp;...Trovagene inks seven deals for commercialization of liquid biopsy tests ex-US - Seeking Alpha'
p3
aS'Trovagene announces a reorganization to accelerate global distribution of ... PR Newswire  - Dec 13, 2016 SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, announced today that it will increase its focus on the global distribution of kits and systems to clinical&nbsp;...Trovagene to Focus More on Liquid Biopsy Testing Market - Yahoo FinanceTrovagene Axes 20 Staffers, Refocuses on Distributing Kits, Systems - Genetic Engineering & Biotechnology News'
p4
aS'Trovagene to Announce Fourth Quarter and Year End 2016 Financial Results and ... PR Newswire  - Mar 1, 2017 SAN DIEGO, March 1, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, announced today that it will report financial results for the fourth quarter and year ended December 31, 2016&nbsp;...'
p5
aS'Trovagene to Attend the 29th Annual ROTH Conference PR Newswire  - Feb 28, 2017 SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, is scheduled to attend the 29th Annual ROTH Conference, March 12-15, 2017, at the Ritz Carlton Laguna&nbsp;...'
p6
aS'Steel Dynamics, Inc. , TrovaGene, Inc.  Stock Eyes Ahead of Earnings The USA Commerce - Mar 21, 2017 While trading at volume above than average, TrovaGene, Inc.  previous 52-week high was $6.67 and moved down -77.49% over the same period, trading at a volume of 1.68 million.'
p7
aS'TrovaGene, Inc.  recently purchased by insider Tennant Stanley Post Analyst - 21 hours ago TrovaGene, Inc.  reached -6.52% versus a 1-year low price of $1.05. The stock was last seen -8.51% lower, reaching at $1.08 on Mar. 21, 2017.Unusual Volume Spotted in TrovaGene, Inc.  Stock - Melville ReviewPiperJaffray Downgrades TrovaGene Inc to Underweight - Energy Index'
p8
aS'Investor Center: Technicals in View for Trovagene Inc.  Rives Journal - Mar 21, 2017 Trovagene Inc.  presently has a 14-day Commodity Channel Index  of -192.05. The CCI was created to typically stay within the reading of -100 to +100.'
p9
aS"Analyst's Proposition on TrovaGene, Inc. , The Goldfield Corporation  The USA Commerce - Mar 17, 2017 Presently TrovaGene, Inc.  stock have an ABR of 1.67. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell."
p10
a.